

# Ontario Public Drug Programs Drug Submission Status

---

Generic Name: mometasone furoate dry powder inhaler

Brand Name: Asmanex Twisthaler

Strength: 100mcg/metered inhalation

Manufacturer: Merck Canada Inc.

Indication: As a preventative agent for the prophylactic management of steroid-responsive bronchial asthma in patients 4 years of age and older.

Rapid Review: Not Requested

Submission Type:	Date Submission Received:	Date Submission Deemed Complete:	Review Status:	Funding Status:
First Review: (Initial Submission)	10/04/2015	16/07/2015	Submission complete & under review	N/A

## Rapid Review:

Details of the Rapid Review process can be found at:

[Rapid Review Process](#)

## Review Status:

- Screening - Ministry is screening the manufacturer's submission to ensure all regulatory and policy requirements have been met in order to proceed with the drug review.
- Submission incomplete - Manufacturer did not meet the necessary requirements to allow review to proceed.
- Submission complete & under review - Manufacturer met all requirements to proceed with the drug review, and evaluation of the drug submission is underway.

- Committee to Evaluate Drugs (CED) review completed, manufacturer requesting reconsideration – A recommendation was made by the CED, however the manufacturer has submitted or will be submitting additional information.
- Committee to Evaluate Drugs (CED) review completed - A recommendation was made by the CED.
- Ontario Steering Committee for Cancer Drugs (OSCCD) review completed-A recommendation was made by the OSCCD.
- Executive Officer (EO) decision rendered.

## Funding Status:

The Committee to Evaluate Drugs (CED) recommendation and the Executive Officer (EO) decision, if available, can be found at:

[The CED recommendation and the EO decision](#)

Updated: October 27, 2015